Development and Manufacturing Strategy for DNA-Based Drug/Vaccine Candidates with Live Q&A

DNA vaccines have emerged as a promising technology for developing COVID-19 vaccines due to their ability to be quickly designed and manufactured after obtaining the pathogen or cancer antigen genome sequence. The recent approval of ZyCoV-D, the first DNA vaccine for COVID-19 for emergency use has demonstrated this efficacy.

However, utilizing novel technology platforms and development paradigms may increase the risks which requires careful safety evaluation. As a result, it is critical to ensure the quality of the naked plasmid from its source in order to satisfy the stringent requirements of DNA vaccines and drugs.

To this end, GenScript ProBio has developed a plasmid DNA platform and a viral vector platform, and has accumulated extensive expertise in manufacturing plasmids for various applications, including raw materials, drug substances, and even drug products. From preclinical to clinical to commercial supply, GenScript ProBio is dedicated to supporting the success of more gene and cell therapies.